Pasithea Therapeutics Corp. (KTTA)
| Market Cap | 13.36M +149.6% |
| Revenue (ttm) | n/a |
| Net Income | -21.29M |
| EPS | -1.11 |
| Shares Out | 33.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 628,873 |
| Open | 0.3956 |
| Previous Close | 0.4049 |
| Day's Range | 0.3720 - 0.4120 |
| 52-Week Range | 0.2810 - 2.0600 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About KTTA
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary scle... [Read more]
Financial Performance
Financial StatementsNews
Pasithea Therapeutics announces PAS-004 data at ESMO
Pasithea Therapeutics (KTTA) announced updated safety, tolerability, and preliminary efficacy data from its ongoing Phase 1 dose-escalation study of PAS-004 monotherapy in a heavily pre-treated popula...
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once dai...
Pasithea Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
PAS-004 is being tested in NF1, where cutaneous lesions have substantial unmet need and no approved systemic treatment. Initial Phase Ib data are expected next month, with dose selection for expansion targeted around Q1 or Q2 next year.
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poste...
Pasithea Therapeutics Transcript: AGM 2026
The meeting approved the election of two directors, ratified the independent auditors, and authorized a reverse stock split at a flexible ratio. No questions were raised, and all proposals passed by majority vote.
Pasithea Therapeutics Slides: Corporate presentation
Pasithea Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conferen...
Pasithea Therapeutics Quarterly report: Q2 2026
Pasithea Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Pasithea Therapeutics Slides: Corporate presentation
Pasithea Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Pasithea Therapeutics Proxy statement: Proxy filing
Pasithea Therapeutics filed a proxy statement on August 7, 2026, providing details for shareholder voting and corporate governance matters.
Pasithea Therapeutics Proxy statement: Proxy filing
Pasithea Therapeutics filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
Pasithea Therapeutics Slides: Corporate presentation
Pasithea Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 29, 2026.
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presen...
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyc...
Pasithea Therapeutics announces updated data from PAS-004 trial
Pasithea Therapeutics (KTTA) announced updated interim safety and clinical activity data from its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tu...
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal tr...
Pasithea Therapeutics announces amendments to PAS-004 clinical study
Pasithea Therapeutics (KTTA) announced it has amended the clinical study protocol for the Phase 1/1b trial of PAS-004 in neurofibromatosis type 1 patients with symptomatic inoperable, incompletely res...
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
-- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp....
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference
-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with P...
Pasithea Therapeutics Transcript: Transcript
PAZ004, a macrocyclic MEK inhibitor, is advancing through clinical trials for NF1 and advanced cancers, showing a differentiated safety and PK profile with promising early efficacy. The program targets significant unmet needs, especially in cutaneous neurofibroma, and is supported by strong patent protection and recent financing.
Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA
Pasithea Therapeutics (KTTA) announced that the FDA has granted Orphan Drug Designation to PAS-004 for the treatment of Amyotrophic Lateral Sclerosis, or ALS.
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyc...
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
The FDA granted Pasithea Therapeutics (KTTA) orphan designation for a treatment of amyotrophic lateral sclerosis, according to a post to the agency’s site.
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
Pasithea Therapeutics (KTTA) announced the appointment of Kartik Krishnan as chief medical officer of the company, effective May 1. Krishnan will oversee all clinical development and medical strategy ...
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocycl...